• 1
    Pfeifer-Ott B, Godfrey J. Patients report many different signs and symptoms as indicators of impending flare in atopic eczema. J Eur Acad Dermatol Venereol 2003;17(Suppl. 3):181.
  • 2
    McCuaig C. The itch that rashes: an update on atopic dermatitis. Can J Diagnosis 2003;20: 6976.
  • 3
    Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002;11: 1224.
  • 4
    Giannetti A, Fantini F, Cimitan A, Pincelli C. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992;176: 9092.
  • 5
    Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol 2003;139: 14631470.
  • 6
    Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990;70: 323329.
  • 7
    Herman SM, Vender RB. Antihistamines in the treatment of atopic dermatitis. J Cutan Med Surg 2003;7: 467473.
  • 8
    Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003;148: 12121221.
  • 9
    Boguniewicz M. Treatment options and new therapeutic approaches in atopic dermatitis. Dermatol Nurs 2003;(Suppl.):1218.
  • 10
    Savin JA, Paterson WD, Adam K, Oswald I. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol 1979;115: 313315.
  • 11
    Doxepin cream for eczema? Drug Ther Bull 2000;38: 3132.
  • 12
    Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141: 264273.
  • 13
    Kalthoff FS, Chung J, Stuetz A. Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol 2002;130: 8592. Erratum in Clin Exp Immunol 2002;130: 562–563.
  • 14
    Winiski A, Wang S, Schwendinger B, Stuetz A. Inhibitory activity of pimecrolimus and tacrolimus on induced cytokine mRNA and protein expression in a human T-cell line (Jurkat) measured via RT-PCR and ELISA. J Invest Dermatol 2002;119: 347 (Abstract 835).
  • 15
    Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998;290: 501507.
  • 16
    Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108: 275280.
  • 17
    Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46: 495504.
  • 18
    Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110: 277284.
  • 19
    Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205: 271277.
  • 20
    Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144: 507513.
  • 21
    Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110: e2.
  • 22
    Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002;14: 414418.
  • 23
    Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75: 800802.
  • 24
    Westfall PH, Krishen A. Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Statist Planning Inference 2001;99: 2540.
  • 25
    Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002;8: 333342.
  • 26
    Ben-Gashir MA. Relationship between quality of life and disease severity in atopic dermatitis/eczema syndrome during childhood. Curr Opin Allergy Clin Immunol 2003;3: 369373.
  • 27
    Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatolog Treat 2003;14: 516.
  • 28
    Wahlgren CF, Hagermark O, Bergstrom R, Hedin B. Evaluation of a new method of assessing pruritus and antipruritic drugs. Skin Pharmacol 1988;1: 313.
  • 29
    Barbier N, Paul C, Luger T, Allen R, de Prost Y, Papp K et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical progamme. Br J Dermatol 2004;150: 96102.
  • 30
    Kaufmann R, Fölster-Holst R, Höger P, Thaçi D, Löffler H, Staab D et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Clin Allergy Immunol 2004;114: 11831188.